Description: Can the global reinsurance market emerge from its recent consistent underperformance and grasp the opportunity to build back a better more model that meets the demands of society as a whole as well as its traditional stakeholders

Description: To inform and educate stakeholders for health plans and insurers on novel ways to optimize reinsurance structures to meet capital related goals and boost RBC and liquidity ratios. In lieu of traditional market-based financial instruments involving equity and/or debt, a quota share transaction can be used with potentially far more attractive terms and achieving essentially the same result.

Description: Reinsurance News co-editor Ronald Poon-Affat discusses the morality and ethics involved in life insurance

Description: In this interview, Caroline Grégoire, formerly from Hannover Re, and now international mentor, coach, trainer and speaker, shares her views on how mentoring can support you on your career path and how it also benefits the reinsurance industry as a whole.

Description: Feature article discussing one of the themes of last year’s Living to 100 Symposium; socio-economic differences in mortality.

Description: This article summarizes insights from a 2021 survey of more than 40 life insurance companies with a focus on trends in reinsurand and in-force management. While reinsurance objectives and methods have remained steadfast in a sea of economic and regulatory impacts, life companies still are looking at different solutions to make improvements in profitability, stability, and scale.

Description: Re/insurance rates have been increasing since 2018, although pricing momentum has decelerated recently. Insurers and reinsurers are working to enhance profitability and improve the value proposition for clients in an environment of uncertainty about natural catastrophes, COVID-19-related losses, and social inflation, among other factors. This article describes drivers of the current underwriting cycle, compares it with past cycles, and provides considerations for the future.

Description: Cell and Gene Therapy (CGT) are life-changing treatments where conditions such as cancer, hemophilia, spinal muscular atrophy and blindness are being cured. These are great for individuals and society, but the treatment costs are expensive which is bad for payers and reinsurers. This article explores ways for health reinsurance actuaries to participate in the space and evaluate the risk associated with these treatments

Description: Highlights the key takeaways from the 2021 published SOA PLT study on lapse and mortality experience of US term plans in the post level term period. This article explains the new insights in the latest study including a comparison of PLT experience between Jump to ART and Graded structures. The important variables driving PLT experience and the relationship between lapse and mortality experience are also discussed.

Description: This article highlights some key implications for reinsurance contract held and loss-recovery component IFRS 17.